The latest trading session saw Viking Therapeutics, Inc. (VKTX) ending at $32.87, denoting a +0.67% adjustment from its last day's close. The stock's performance was behind the S&P 500's daily ...

Macquarie University researchers have worked with an international team of scientists to achieve a major milestone in synthetic biology by completing the creation of the final chromosome in the ...

Shares of Summit Therapeutics (NASDAQ: SMMT) had jumped 14.3% at 11:31 a.m. ET on Tuesday. The nice gain came after reports that H.C. Wainwright analyst Mitchell Kapoor maintained a "buy" rating ...

The upstart, clinical stage biotech company Viking Therapeutics, Inc. (NASDAQ:VKTX), which is attempting to disrupt their market leadership has also suffered from a protracted hangover ...

However, Wall Street's enthusiasm for Summit Therapeutics appears to be justified. If ivonescimab fulfills its potential, Summit should be worth a lot more within a few years than it is today.

One company currently utilising this approach is Tessera Therapeutics, which emerged in 2020 and was able to secure $300 million earlier this year, in a recent Series C financing round.

Competitors such as Beam Therapeutics and Tessera Therapeutics are making progress with their own gene editing technologies, which could potentially offer advantages over CRISPR's approach.